Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Crinetics Pharmaceuticals Inc shares valued at $3,151,625 were purchased by STEPHEN BETZ on Jun 12 ’25. At $32.33 per share, STEPHEN BETZ acquired 97,483 shares.
Also, Pizzuti Dana sold 2,515 shares, netting a total of over 86,021 in proceeds. Following the sale of shares at $34.20 each, the insider now holds 72,233 shares.
Before that, Knight Jeff E. had sold 7,162 shares from its account. In a trade valued at $244,964, the Chief Operating Officer traded Crinetics Pharmaceuticals Inc shares for $34.20 each. Upon closing the transaction, the insider’s holdings decreased to 7,162 shares, worth approximately $2.81 million.
As published in their initiating research note from Stifel on March 25, 2025, Crinetics Pharmaceuticals Inc [CRNX] has been a Buy and the price target has been revised to $60. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in mid February. As of February 04, 2025, Wolfe Research has initiated its “Peer perform” rating for CRNX. Earlier on January 22, 2025, Jefferies upgraded its rating. Their new recommendation was “a Buy” for CRNX stock which previously was a “a Hold”.
Analyzing CRNX Stock Performance
On last trading session,, Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] plunged -0.49% to $32.17. The stock’s lowest price that day was $31.73, but it reached a high of $32.65 in the same session. During the last five days, there has been a drop of approximately -0.46%. Over the course of the year, Crinetics Pharmaceuticals Inc shares have dropped approximately -37.08%.
Support And Resistance Levels for Crinetics Pharmaceuticals Inc (CRNX)
RSI (Relative Strength Index) is 52.82 on the 14-day chart, showing neutral technical sentiment.
Is Crinetics Pharmaceuticals Inc subject to short interest?
Stocks of Crinetics Pharmaceuticals Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.38 million shares to 10.21 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 9.84 million shares. A jump of 3.67% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 11.14 of the overall float, the days-to-cover ratio (short ratio) jumped to 11.14.
Which companies own the most shares of Crinetics Pharmaceuticals Inc (CRNX)?
In terms of Crinetics Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 75.5 in the next 12 months, up nearly 133.53% from the previous closing price of $32.33. Analysts anticipate Crinetics Pharmaceuticals Inc stock to reach 91 by 2025, with the lowest price target being 60. In spite of this, 5 analysts ranked Crinetics Pharmaceuticals Inc stock as Buy at the end of 2025. On March 06, 2024, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $68.
